RecruitingACTRN12622001165774

Survivorship Care For Long-Term Responder Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC): Feasibility of a Multi-Disciplinary Team (MDT) Consultation


Sponsor

Chris O'Brien Lifehouse

Enrollment

30 participants

Start Date

Jan 25, 2023

Study Type

Interventional

Conditions

Summary

This study aims to test if it is practical to conduct a one-off multi-disciplinary team (MDT) consultation for patients with advanced non-small cell lung cancer, focussing on survivorship care needs. Who is it for? You may be eligible to join this study if you are aged 18 years or older, have advanced non-small cell lung cancer, and have been receiving your current cancer treatment for at least 6 months without the disease getting worse on scans. Study details All patients who enrol in this study will be invited to participate in a single, 30-minute, multi-disciplinary team (MDT) meeting via a secure, online video-conferencing platform. The meeting will focus on any unmet needs and concerns the participating patient may have related to survivorship, with discussion led by a lung cancer specialist nurse from the hospital. The MDT will include the patient (+/- a family member), hospital doctor, allied health professional, and a member of the patient’s primary care team (ideally the patient’s GP). Prior to the MDT meeting, all patients will be asked to complete a survey to identify survivorship concerns in order to guide the MDT discussion, and they will receive a 15-minute call by a member of the study team prior to the MDT meeting. The patient’s GP will also be asked to complete a 5-minute questionnaire prior to the MDT. After the MDT meeting a survivorship care plan will be produced summarising the discussion at the MDT meeting, and a copy made available to the patient, the patient’s GP and placed in the patient’s hospital record. Three months after the MDT meeting, participating patients and GPs will be asked to complete a short follow-up questionnaire about how acceptable the MDT meeting process was. Later on (4-4.5 months post participating in the MDT meeting) some patients and their GPs will also be invited to participate in an interview to discuss their impressions of participating in the MDT meeting. Rationale It is hoped that this study will show that a MDT consultation is both feasible and acceptable to patients, hospital and community-based health-care providers, and enable further implementation of these consultations to improve the survivorship care for patients living with advanced non-small cell lung cancer.


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

Living with advanced non-small cell lung cancer for a long period brings its own set of challenges beyond the cancer itself — ongoing fatigue, emotional strain, financial stress, and managing relationships with doctors and loved ones. Many patients in this situation have survivorship needs that are not well addressed in standard oncology appointments, which tend to focus primarily on the cancer treatment itself. This study is testing whether a single 30-minute online meeting with a team of healthcare professionals (including a lung cancer nurse, oncologist, allied health professional, and your GP) can meaningfully address these unmet needs and produce a personalised survivorship care plan. Before the meeting, you complete a brief survey about your concerns. Afterward, your care plan is shared with your medical team and GP. You may be eligible if you are 18 or older, have been diagnosed with advanced non-small cell lung cancer, have been on your current treatment for at least 6 months without the disease getting worse on scans, and have access to a computer with internet. You need to be able to communicate in English without an interpreter. The study excludes patients whose treatment is intended to cure the cancer, since those patients have different care needs.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

One-off, virtual, survivorship-focussed multi-disciplinary team (MDT) consultation. MDT consultation conducted within 4 (ideally) to 6 (maximum) weeks post participant recruitment to study Inter

One-off, virtual, survivorship-focussed multi-disciplinary team (MDT) consultation. MDT consultation conducted within 4 (ideally) to 6 (maximum) weeks post participant recruitment to study Intervention: MDT-consultation attended by: 1. Hospital-based team (Minimum: 1 lung cancer specialist clinical nurse, 1 allied health staff, 1 oncology doctor*) *For the doctor representative, attendance during the first 10 minutes only of the MDT consultation is required. 2. Primary-care clinician 3. Patient participant (+/- 1 family member) Setting: • Secure online video-conferencing platform • One-off structured discussion of 30 minutes per patient discussed, led by lung specialist clinical nurse Procedure: • Eligible patients identified via hospital clinics, referred by clinicians or self-referred • Consented study participants referred to MDT-coordinator who arranges survivorship needs screening prior to MDT-consultation o 1st standardised participant questionnaire (~20 minutes) o 2nd Brief phone call (~15 minutes) with one of lung cancer specialist clinical nurse OR lung fellow or registrar following completion of participant questionnaire and pre MDT consultation • Structured survivorship MDT consultation (encompassing discussion of unmet survivorship needs and concerns as guided by questionnaire) led by lung cancer specialist clinical nurse with output being the formulation of a structured, individualised Survivorship Care Plan (SCP) • SCP forwarded to patient participant, patient’s own GP, and made available in hospital medical records for hospital-based clinicians


Locations(1)

NSW, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12622001165774